Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:16R-HETE)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST001856 AN003009 The metabolomic resetting effect of FG4592 in AKI to CKD transition-day 21 (Part 2) Kidney Mouse Kidney disease Children's Hospital of Nanjing Medical University AUC
ST001951 AN003176 Quantification of ω-3 fatty acids and their derivatives in lungs from hypoxia-induced pulmonary hypertension (PH) mice. Lung Mouse Pulmonary hypertension University of Tokyo ng/mg tissue
ST000004 AN000004 Lipidomics studies on NIDDK / NIST human plasma samples Blood Human LIPID MAPS nM
ST000916 AN001491 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma Blood Human Fatty liver disease LIPID MAPS nM
ST002216 AN003625 Non-targeted metabolomics screen comparing metabolite profiles of serum from PDAC-bearing mice that received metronidazole using high-resolution, high-performance LC-MS/MS analysis. Blood Mouse Cancer The Wistar Institute Normalized Peak Area
ST001206 AN002008 Effects of cold exposure on serum lipidomic in mice Blood Mouse Joslin Diabetes Center - Harvard Medical School Peak area
ST001207 AN002009 Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 Blood Mouse Joslin Diabetes Center - Harvard Medical School Peak area
ST001213 AN002024 Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice Blood Mouse Joslin Diabetes Center - Harvard Medical School Peak area
ST001214 AN002025 Lipidommics in the serum of human subjects Blood Human Joslin Diabetes Center - Harvard Medical School Peak area
ST001215 AN002026 Effect of Mirabegron Treatment on serum lipidome Blood Human Joslin Diabetes Center - Harvard Medical School Peak area
ST001154 AN001945 A comprehensive plasma metabolomics dataset for a cohort of mouse knockouts within the International Mouse Phenotyping Consortium Blood Mouse University of California Peak height normalized with creatinine
ST000915 AN001485 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver Liver Human Fatty liver disease LIPID MAPS pmol/mg
  logo